{
    "id": "correct_subsidiary_00055_0",
    "rank": 18,
    "data": {
        "url": "https://patents.google.com/patent/EP0648127A4/en",
        "read_more_link": "",
        "language": "en",
        "title": "EP0648127A4 - Type i and type ii surface antigens associated with staphylococcus epidermidis. - Google Patents",
        "top_image": "",
        "meta_img": "",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "1991-11-22T00:00:00",
        "summary": "",
        "meta_description": "A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://patents.google.com/patent/EP0648127A4/en",
        "text": "Type i and type ii surface antigens associated with staphylococcus epidermidis.\n\nInfo\n\nPublication number\n\nEP0648127A4\n\nEP0648127A4 EP92924432A EP92924432A EP0648127A4 EP 0648127 A4 EP0648127 A4 EP 0648127A4 EP 92924432 A EP92924432 A EP 92924432A EP 92924432 A EP92924432 A EP 92924432A EP 0648127 A4 EP0648127 A4 EP 0648127A4\n\nAuthority\n\nEP\n\nEuropean Patent Office\n\nPrior art keywords\n\ntype\n\nepidermidis\n\nsurface antigens\n\nstaphylococcus epidermidis\n\nserotypes\n\nPrior art date\n\n1991-11-22\n\nLegal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)\n\nGranted\n\nApplication number\n\nEP92924432A\n\nOther languages\n\nGerman (de)\n\nFrench (fr)\n\nOther versions\n\nEP0648127B1 (en\n\nEP0648127A1 (en\n\nInventor\n\nAli Ibrahim Fattom\n\nD Craig Wright\n\nWalter W Karakawa\n\nCurrent Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)\n\nVaxart Inc\n\nOriginal Assignee\n\nUnivax Biologics Inc\n\nPriority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)\n\n1991-11-22\n\nFiling date\n\n1992-11-20\n\nPublication date\n\n1995-06-14\n\n1992-11-20 Application filed by Univax Biologics Inc filed Critical Univax Biologics Inc\n\n1995-04-19 Publication of EP0648127A1 publication Critical patent/EP0648127A1/en\n\n1995-06-14 Publication of EP0648127A4 publication Critical patent/EP0648127A4/en\n\n2003-04-16 Application granted granted Critical\n\n2003-04-16 Publication of EP0648127B1 publication Critical patent/EP0648127B1/en\n\n2012-11-20 Anticipated expiration legal-status Critical\n\nStatus Expired - Lifetime legal-status Critical Current\n\nLinks\n\nEspacenet\n\nEPO GPI\n\nEP Register\n\nGlobal Dossier\n\nDiscuss\n\n241000191963 Staphylococcus epidermidis Species 0.000 title abstract 5\n\n239000000427 antigen Substances 0.000 title abstract 3\n\n102000036639 antigens Human genes 0.000 title abstract 3\n\n108091007433 antigens Proteins 0.000 title abstract 3\n\n208000015181 infectious disease Diseases 0.000 abstract 2\n\n108060003951 Immunoglobulin Proteins 0.000 abstract 1\n\n238000012258 culturing Methods 0.000 abstract 1\n\n150000004676 glycans Chemical class 0.000 abstract 1\n\n230000000521 hyperimmunizing effect Effects 0.000 abstract 1\n\n230000003053 immunization Effects 0.000 abstract 1\n\n238000002649 immunization Methods 0.000 abstract 1\n\n102000018358 immunoglobulin Human genes 0.000 abstract 1\n\n238000000034 method Methods 0.000 abstract 1\n\n229920001282 polysaccharide Polymers 0.000 abstract 1\n\n239000005017 polysaccharide Substances 0.000 abstract 1\n\nClassifications\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K39/00—Medicinal preparations containing antigens or antibodies\n\nA61K39/02—Bacterial antigens\n\nA61K39/085—Staphylococcus\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS\n\nA61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics\n\nA61P31/04—Antibacterial agents\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS\n\nA61P37/00—Drugs for immunological or allergic disorders\n\nA61P37/02—Immunomodulators\n\nA61P37/04—Immunostimulants\n\nC—CHEMISTRY; METALLURGY\n\nC07—ORGANIC CHEMISTRY\n\nC07K—PEPTIDES\n\nC07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies\n\nC07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria\n\nC07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria\n\nC07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE\n\nC12P19/00—Preparation of compounds containing saccharide radicals\n\nC12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K39/00—Medicinal preparations containing antigens or antibodies\n\nLandscapes\n\nHealth & Medical Sciences (AREA)\n\nChemical & Material Sciences (AREA)\n\nLife Sciences & Earth Sciences (AREA)\n\nOrganic Chemistry (AREA)\n\nGeneral Health & Medical Sciences (AREA)\n\nImmunology (AREA)\n\nMedicinal Chemistry (AREA)\n\nEngineering & Computer Science (AREA)\n\nMicrobiology (AREA)\n\nAnimal Behavior & Ethology (AREA)\n\nPharmacology & Pharmacy (AREA)\n\nPublic Health (AREA)\n\nVeterinary Medicine (AREA)\n\nZoology (AREA)\n\nChemical Kinetics & Catalysis (AREA)\n\nGeneral Chemical & Material Sciences (AREA)\n\nWood Science & Technology (AREA)\n\nGenetics & Genomics (AREA)\n\nBiochemistry (AREA)\n\nBioinformatics & Cheminformatics (AREA)\n\nEpidemiology (AREA)\n\nGeneral Engineering & Computer Science (AREA)\n\nMolecular Biology (AREA)\n\nProteomics, Peptides & Aminoacids (AREA)\n\nBiotechnology (AREA)\n\nNuclear Medicine, Radiotherapy & Molecular Imaging (AREA)\n\nMycology (AREA)\n\nBiophysics (AREA)\n\nCommunicable Diseases (AREA)\n\nOncology (AREA)\n\nPeptides Or Proteins (AREA)\n\nMedicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)\n\nPreparation Of Compounds By Using Micro-Organisms (AREA)\n\nAcyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)\n\nMicro-Organisms Or Cultivation Processes Thereof (AREA)\n\nAbstract\n\nA process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.\n\nEP92924432A 1991-11-22 1992-11-20 Type i surface antigens associated with staphylococcus epidermidis Expired - Lifetime EP0648127B1 (en)\n\nApplications Claiming Priority (3)\n\nApplication Number Priority Date Filing Date Title US79625291A 1991-11-22 1991-11-22 US796252 1991-11-22 PCT/US1992/009784 WO1993009811A1 (en) 1991-11-22 1992-11-20 TYPE I AND TYPE II SURFACE ANTIGENS ASSOCIATED WITH $i(STAPHYLOCOCCUS EPIDERMIDIS)\n\nPublications (3)\n\nPublication Number Publication Date EP0648127A1 EP0648127A1 (en) 1995-04-19 EP0648127A4 true EP0648127A4 (en) 1995-06-14 EP0648127B1 EP0648127B1 (en) 2003-04-16\n\nFamily\n\nID=25167715\n\nFamily Applications (1)\n\nApplication Number Title Priority Date Filing Date EP92924432A Expired - Lifetime EP0648127B1 (en) 1991-11-22 1992-11-20 Type i surface antigens associated with staphylococcus epidermidis\n\nCountry Status (12)\n\nCountry Link US (2) US5866140A (en) EP (1) EP0648127B1 (en) JP (2) JP4087896B2 (en) AT (1) ATE237351T1 (en) AU (1) AU681573B2 (en) CA (1) CA2123811C (en) DE (1) DE69233012T2 (en) DK (1) DK0648127T3 (en) ES (1) ES2198405T3 (en) FI (1) FI111336B (en) NO (1) NO319013B1 (en) WO (1) WO1993009811A1 (en)\n\nFamilies Citing this family (36)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use US7279162B1 (en) 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection US5955074A (en) * 1990-10-22 1999-09-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection JP4160633B2 (en) * 1994-09-21 2008-10-01 ãã³ãªã¼ ã¨ã ï¼ã¸ã£ã¯ã½ã³ ãã¡ã¦ã³ãã¼ã·ã§ã³ ãã©ã¼ ã¶ ã¢ããã³ã¹ã¡ã³ã ãªã ããªã¿ãªã¼ ã¡ãã£ã¹ã³ Opsonizing antibodies that react extensively with common staphylococcal antigens US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies WO2000012132A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of Î²-glucans and specific antibodies EP1121135B1 (en) * 1998-09-14 2009-01-28 Nabi Biopharmaceuticals Compositions of beta-glucans and specific immunoglobulins US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins US6703492B1 (en) 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins CA2501077C (en) 2002-11-12 2016-06-21 Gerald B. Pier Polysaccharide vaccine for staphylococcal infections WO2004043407A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei EP2298341A3 (en) 2004-10-21 2011-07-13 Wyeth LLC Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection CA2611023A1 (en) 2005-06-13 2006-12-21 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections NZ574057A (en) 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen US7754225B2 (en) * 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection AU2008280799B2 (en) * 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same RU2532911C2 (en) 2008-07-21 2014-11-20 ÐÐ·Ðµ ÐÑÐ¸Ñ ÑÐ¼ Ð­Ð½Ð´ Ð£Ð¸Ð¼ÐµÐ½'Ð Ð¥Ð¾ÑÐ¿Ð¸ÑÐ°Ð», ÐÐ½Ðº. Methods and compositions described as synthetic beta-1,6-glucosaminoligosaccharides JP2012530785A (en) 2009-06-22 2012-12-06 ã¯ã¤ã¹ã»ã¨ã«ã¨ã«ã·ã¼ Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens JP5914344B2 (en) 2009-10-30 2016-05-11 ããã«ãã£ã¹ ã¢ã¼ã²ã¼ Purification of Staphylococcus aureus type 5 and type 8 capsular saccharides WO2012075428A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae CN113730648B (en) * 2021-09-06 2022-11-01 æ¸©å·çå¸ç¹çç©ç§ææéå ¬å¸ Hydrogel combined with staphylococcus epidermidis and application of hydrogel in treatment of wound surfaces\n\nCitations (2)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title EP0302781A1 (en) * 1987-08-03 1989-02-08 Institut Pasteur Process for obtaining staphylococcal capsule polysaccharides, uses of these polysaccharides and strains for putting this process into operation WO1990003398A1 (en) * 1988-09-28 1990-04-05 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use\n\nFamily Cites Families (3)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title JPS5452794A (en) * 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens\n\n1992\n\n1992-11-20 CA CA002123811A patent/CA2123811C/en not_active Expired - Lifetime\n\n1992-11-20 WO PCT/US1992/009784 patent/WO1993009811A1/en active IP Right Grant\n\n1992-11-20 ES ES92924432T patent/ES2198405T3/en not_active Expired - Lifetime\n\n1992-11-20 JP JP50941193A patent/JP4087896B2/en not_active Expired - Lifetime\n\n1992-11-20 AT AT92924432T patent/ATE237351T1/en active\n\n1992-11-20 DK DK92924432T patent/DK0648127T3/en active\n\n1992-11-20 DE DE69233012T patent/DE69233012T2/en not_active Expired - Lifetime\n\n1992-11-20 EP EP92924432A patent/EP0648127B1/en not_active Expired - Lifetime\n\n1992-11-20 AU AU30747/92A patent/AU681573B2/en not_active Expired\n\n1994\n\n1994-05-19 NO NO19941877A patent/NO319013B1/en not_active IP Right Cessation\n\n1994-05-20 FI FI942359A patent/FI111336B/en not_active IP Right Cessation\n\n1994-12-22 US US08/361,821 patent/US5866140A/en not_active Expired - Lifetime\n\n1995\n\n1995-06-07 US US08/472,211 patent/US5961975A/en not_active Expired - Lifetime\n\n2003\n\n2003-12-24 JP JP2003428138A patent/JP4353789B2/en not_active Expired - Lifetime\n\nPatent Citations (2)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title EP0302781A1 (en) * 1987-08-03 1989-02-08 Institut Pasteur Process for obtaining staphylococcal capsule polysaccharides, uses of these polysaccharides and strains for putting this process into operation WO1990003398A1 (en) * 1988-09-28 1990-04-05 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use\n\nNon-Patent Citations (1)\n\n* Cited by examiner, â Cited by third party Title ICHIMAN Y. ET AL., CANADIAN JOURNAL OF MICROBILOGY, vol. 37, no. 5, pages 404 - 407 *\n\nAlso Published As\n\nPublication number Publication date JP4087896B2 (en) 2008-05-21 FI942359A0 (en) 1994-05-20 EP0648127B1 (en) 2003-04-16 NO941877D0 (en) 1994-05-19 ES2198405T3 (en) 2004-02-01 NO319013B1 (en) 2005-06-06 AU3074792A (en) 1993-06-15 EP0648127A1 (en) 1995-04-19 CA2123811C (en) 2005-07-05 FI942359A (en) 1994-05-20 CA2123811A1 (en) 1993-05-27 DE69233012T2 (en) 2003-11-06 US5866140A (en) 1999-02-02 FI111336B (en) 2003-07-15 ATE237351T1 (en) 2003-05-15 AU681573B2 (en) 1997-09-04 DE69233012D1 (en) 2003-05-22 NO941877L (en) 1994-06-16 US5961975A (en) 1999-10-05 JPH07508498A (en) 1995-09-21 DK0648127T3 (en) 2003-05-19 JP2004155789A (en) 2004-06-03 JP4353789B2 (en) 2009-10-28 WO1993009811A1 (en) 1993-05-27\n\nSimilar Documents\n\nPublication Publication Date Title EP0648127A4 (en) 1995-06-14 Type i and type ii surface antigens associated with staphylococcus epidermidis. EP0077734A3 (en) 1984-04-04 Production of monoclonal antibodies against bacterial adhesins ATE70309T1 (en) 1991-12-15 HUMAN MONOCLONAL ANTIBODIES AGAINST BACTERIAL TOXINS. ATE188708T1 (en) 2000-01-15 ANTIBODIES DERIVATIVES WO1995006732A3 (en) 1995-06-01 Bacterial exported proteins and acellular vaccines based thereon ATE7761T1 (en) 1984-06-15 VACCINE AND PRODUCTION PROCESS. SE8703225L (en) 1988-02-21 MONOCLONAL ANTIBODIES AND PEPTIDES USEFUL IN TREATMENT AND DIAGNOSTIZATION OF HIV INFECTIONS OA09802A (en) 1994-04-15 Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus. EP0041897A3 (en) 1982-07-14 Polysaccharide antigen from streptococcus and vaccine containing the same EP0135073A3 (en) 1987-05-27 Antigens and monoclonal antibodies reactive against merozites of eimeria spp. SE9000333D0 (en) 1990-01-31 MONOCLONAL ANTIBODY AU2456888A (en) 1989-10-05 Monoclonal antibodies specific for HIV and hybridomas for their production YU22693A (en) 1997-01-08 RECOMBINANT HUMAN MONOCLONAL ANTITLES THAT NEUTRALIZE HIV FOR THE PREVENTION AND TREATMENT OF HIV INFECTION EP0327648A4 (en) 1989-03-16 Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient. DE69025629D1 (en) 1996-04-04 MEDICINAL PRODUCT AND METHOD FOR TREATING ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) AND AIDS-RELATED COMPLEX USING CARBOHYDRATE-SPECIFIC ANTIBODIES ZA916313B (en) 1993-04-28 New use of a monoclonal antibody DE3381985D1 (en) 1990-12-13 USE OF PEPTIDES. BG51639A1 (en) 1993-07-15 Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain &#34; hantaan &#34; of the virus of haemorrhagic fever with nephritic syndrome Lafon et al. 1988 Production of human monoclonal antibodies neutralizing rabies virus: An alternative to rabies immune globulin of human blood donation RU93058456A (en) 1997-01-20 ANTIBODIES, DIAGNOSTIC METHODS, TREATMENT METHOD, PHARMACEUTICAL COMPOSITION, CELL LINES SU1692146A1 (en) 2000-03-20 HYBRID ANIMAL CULTIVATED ANIMAL CELLS STRAIN MUS MUSCULUS L. - PRODUCER OF MONOCLONAL ANTIBODIES TO 146 S-COMPONENT OF THE VASCUS VIRUS O EP0368466A3 (en) 1991-04-17 Compositions and methods for the treatment and prevention of gram-negative bacterial infections BG51640A1 (en) 1993-07-15 Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenous determinant, common for the strains &#34; hantaan &#34; and &#34; bulgarian &#34; of the virus of haemorrhagic fever with nephritic syndrome NO941347L (en) 1987-08-10 Process for the preparation of a human monoclonal antibody RU92016461A (en) 1997-01-10 CULTURE, CELL LINE, MONOCLONAL ANTIBODIES, METHOD FOR OBTAINING MONOCLONAL ANTIBODIES, TREATMENT METHOD, DIAGNOSTIC METHOD\n\nLegal Events\n\nDate Code Title Description 1995-03-03 PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase\n\nFree format text: ORIGINAL CODE: 0009012\n\n1995-04-19 17P Request for examination filed\n\nEffective date: 19940607\n\n1995-04-19 AK Designated contracting states\n\nKind code of ref document: A1\n\nDesignated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE\n\n1995-06-14 A4 Supplementary search report drawn up and despatched\n\nEffective date: 19950425\n\n1995-06-14 AK Designated contracting states\n\nKind code of ref document: A4\n\nDesignated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE\n\n1998-09-23 17Q First examination report despatched\n\nEffective date: 19980806\n\n2002-02-11 GRAG Despatch of communication of intention to grant\n\nFree format text: ORIGINAL CODE: EPIDOS AGRA\n\n2002-07-10 GRAH Despatch of communication of intention to grant a patent\n\nFree format text: ORIGINAL CODE: EPIDOS IGRA\n\n2002-07-12 GRAG Despatch of communication of intention to grant\n\nFree format text: ORIGINAL CODE: EPIDOS AGRA\n\n2002-08-02 GRAG Despatch of communication of intention to grant\n\nFree format text: ORIGINAL CODE: EPIDOS AGRA\n\n2002-08-02 GRAH Despatch of communication of intention to grant a patent\n\nFree format text: ORIGINAL CODE: EPIDOS IGRA\n\n2002-09-18 RTI1 Title (correction)\n\nFree format text: TYPE I SURFACE ANTIGENS ASSOCIATED WITH STAPHYLOCOCCUS EPIDERMIDIS\n\n2003-01-10 GRAH Despatch of communication of intention to grant a patent\n\nFree format text: ORIGINAL CODE: EPIDOS IGRA\n\n2003-02-28 GRAA (expected) grant\n\nFree format text: ORIGINAL CODE: 0009210\n\n2003-04-16 AK Designated contracting states\n\nDesignated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE\n\n2003-04-16 REG Reference to a national code\n\nRef country code: GB\n\nRef legal event code: FG4D\n\n2003-04-30 REG Reference to a national code\n\nRef country code: CH\n\nRef legal event code: EP\n\n2003-05-19 REG Reference to a national code\n\nRef country code: DK\n\nRef legal event code: T3\n\n2003-05-28 REG Reference to a national code\n\nRef country code: IE\n\nRef legal event code: FG4D\n\n2003-07-29 REG Reference to a national code\n\nRef country code: SE\n\nRef legal event code: TRGR\n\n2003-09-09 REG Reference to a national code\n\nRef country code: GR\n\nRef legal event code: EP\n\nRef document number: 20030402661\n\nCountry of ref document: GR\n\n2003-09-10 RAP2 Party data changed (patent owner data changed or rights of a patent transferred)\n\nOwner name: NABI\n\n2003-11-03 NLT2 Nl: modifications (of names), taken from the european patent patent bulletin\n\nOwner name: NABI\n\n2003-11-20 PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]\n\nRef country code: LU\n\nFree format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES\n\nEffective date: 20031120\n\n2003-12-15 REG Reference to a national code\n\nRef country code: CH\n\nRef legal event code: PUE\n\nOwner name: NABI BIOPHARMACEUTICALS\n\nFree format text: UNIVAX BIOLOGICS INCORPORATED#12280 WILKINS AVENUE#ROCKVILLE, MD 20852 (US) $ FATTOM, ALI IBRAHIM#1710 LORRE DRIVE#ROCKVILLE, MD 20852 (US) $ WRIGHT, D. CRAIG#14740 MAIN COVE TERRACE#GAITHERSBURG, MD 20878 (US) -TRANSFER TO- NABI BIOPHARMACEUTICALS#12280 WILKINS AVENUE#ROCKVILLE, MD 20852 (US)\n\n2003-12-17 RAP2 Party data changed (patent owner data changed or rights of a patent transferred)\n\nOwner name: NABI BIOPHARMACEUTICALS\n\n2003-12-19 ET Fr: translation filed 2003-12-31 BECN Be: change of holder's name\n\nOwner name: *NABI BIOPHARMACEUTICALS\n\nEffective date: 20031222\n\n2004-02-01 REG Reference to a national code\n\nRef country code: ES\n\nRef legal event code: FG2A\n\nRef document number: 2198405\n\nCountry of ref document: ES\n\nKind code of ref document: T3\n\n2004-02-02 NLT2 Nl: modifications (of names), taken from the european patent patent bulletin\n\nOwner name: NABI BIOPHARMACEUTICALS\n\n2004-02-20 PLBE No opposition filed within time limit\n\nFree format text: ORIGINAL CODE: 0009261\n\n2004-04-07 26N No opposition filed\n\nEffective date: 20040119\n\n2004-07-15 REG Reference to a national code\n\nRef country code: CH\n\nRef legal event code: NV\n\nRepresentative=s name: MICHELI & CIE INGENIEURS-CONSEILS\n\n2004-09-01 NLS Nl: assignments of ep-patents\n\nOwner name: NABI\n\n2008-04-30 REG Reference to a national code\n\nRef country code: GB\n\nRef legal event code: 732E\n\n2010-08-11 REG Reference to a national code\n\nRef country code: NL\n\nRef legal event code: SD\n\nEffective date: 20100720\n\n2010-09-08 REG Reference to a national code\n\nRef country code: GB\n\nRef legal event code: 732E\n\nFree format text: REGISTERED BETWEEN 20100812 AND 20100818\n\n2011-03-31 PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]\n\nRef country code: GR\n\nPayment date: 20101026\n\nYear of fee payment: 19\n\nRef country code: IT\n\nPayment date: 20101118\n\nYear of fee payment: 19\n\nRef country code: GB\n\nPayment date: 20101022\n\nYear of fee payment: 19\n\n2011-07-07 REG Reference to a national code\n\nRef country code: DE\n\nRef legal event code: R081\n\nRef document number: 69233012\n\nCountry of ref document: DE\n\nOwner name: WRIGHT, D.CRAIG, GAITHERSBURG, US\n\nFree format text: FORMER OWNERS: NABI BIOPHARMACEUTICALS, ROCKVILLE, MD, US; FATTOM, ALI IBRAHIM, ROCKVILLE, MD., US; WRIGHT, D.CRAIG, GAITHERSBURG, MD., US\n\nEffective date: 20110504\n\nRef country code: DE\n\nRef legal event code: R081\n\nRef document number: 69233012\n\nCountry of ref document: DE\n\nOwner name: GLAXO SMITHKLINE BIOLOGICALS SA, BE\n\nFree format text: FORMER OWNERS: NABI BIOPHARMACEUTICALS, ROCKVILLE, MD, US; FATTOM, ALI IBRAHIM, ROCKVILLE, MD., US; WRIGHT, D.CRAIG, GAITHERSBURG, MD., US\n\nEffective date: 20110504\n\nRef country code: DE\n\nRef legal event code: R081\n\nRef document number: 69233012\n\nCountry of ref document: DE\n\nOwner name: FATTOM, ALI IBRAHIM, ROCKVILLE, US\n\nFree format text: FORMER OWNERS: NABI BIOPHARMACEUTICALS, ROCKVILLE, MD, US; FATTOM, ALI IBRAHIM, ROCKVILLE, MD., US; WRIGHT, D.CRAIG, GAITHERSBURG, MD., US\n\nEffective date: 20110504\n\nRef country code: DE\n\nRef legal event code: R081\n\nRef document number: 69233012\n\nCountry of ref document: DE\n\nOwner name: FATTOM, ALI IBRAHIM, US\n\nFree format text: FORMER OWNER: NABI BIOPHARMACEUTICALS,ALI IBRAHIM FATTOM,D.CRAIG WRIGHT, , US\n\nEffective date: 20110504\n\nRef country code: DE\n\nRef legal event code: R081\n\nRef document number: 69233012\n\nCountry of ref document: DE\n\nOwner name: GLAXO SMITHKLINE BIOLOGICALS SA, BE\n\nFree format text: FORMER OWNER: NABI BIOPHARMACEUTICALS,ALI IBRAHIM FATTOM,D.CRAIG WRIGHT, , US\n\nEffective date: 20110504\n\nRef country code: DE\n\nRef legal event code: R081\n\nRef document number: 69233012\n\nCountry of ref document: DE\n\nOwner name: WRIGHT, D.CRAIG, US\n\nFree format text: FORMER OWNER: NABI BIOPHARMACEUTICALS,ALI IBRAHIM FATTOM,D.CRAIG WRIGHT, , US\n\nEffective date: 20110504\n\n2011-07-12 REG Reference to a national code\n\nRef country code: ES\n\nRef legal event code: PC2A\n\nOwner name: GLAXOSMITHKLINE BIOLOGICALS SA\n\nEffective date: 20110630\n\n2012-01-31 PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]\n\nRef country code: CH\n\nPayment date: 20111026\n\nYear of fee payment: 20\n\nRef country code: SE\n\nPayment date: 20111107\n\nYear of fee payment: 20\n\nRef country code: ES\n\nPayment date: 20111123\n\nYear of fee payment: 20\n\nRef country code: DK\n\nPayment date: 20111024\n\nYear of fee payment: 20\n\nRef country code: IE\n\nPayment date: 20111027\n\nYear of fee payment: 20\n\nRef country code: LU\n\nPayment date: 20111129\n\nYear of fee payment: 20\n\nRef country code: FR\n\nPayment date: 20111103\n\nYear of fee payment: 20\n\nRef country code: NL\n\nPayment date: 20111110\n\nYear of fee payment: 20\n\nRef country code: MC\n\nPayment date: 20111027\n\nYear of fee payment: 20\n\n2012-03-23 REG Reference to a national code\n\nRef country code: FR\n\nRef legal event code: TP\n\nOwner name: GLAXOSMITHKLINE BIOLOGICALS SA, BE\n\nEffective date: 20120221\n\n2012-03-30 PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]\n\nRef country code: BE\n\nPayment date: 20111207\n\nYear of fee payment: 20\n\n2012-05-31 PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]\n\nRef country code: DE\n\nPayment date: 20111130\n\nYear of fee payment: 20\n\n2012-11-20 REG Reference to a national code\n\nRef country code: DE\n\nRef legal event code: R071\n\nRef document number: 69233012\n\nCountry of ref document: DE\n\n2012-11-21 REG Reference to a national code\n\nRef country code: DE\n\nRef legal event code: R071\n\nRef document number: 69233012\n\nCountry of ref document: DE\n\n2012-11-26 REG Reference to a national code\n\nRef country code: DK\n\nRef legal event code: EUP\n\n2012-11-28 REG Reference to a national code\n\nRef country code: NL\n\nRef legal event code: V4\n\nEffective date: 20121120\n\n2012-11-30 BE20 Be: patent expired\n\nOwner name: GLAXOSMITHKLINE BIOLOGICALS S.A.\n\nEffective date: 20121120\n\n2012-11-30 REG Reference to a national code\n\nRef country code: CH\n\nRef legal event code: PL\n\n2012-12-12 REG Reference to a national code\n\nRef country code: GB\n\nRef legal event code: PE20\n\nExpiry date: 20121119\n\n2013-01-02 REG Reference to a national code\n\nRef country code: SE\n\nRef legal event code: EUG\n\n2013-01-15 REG Reference to a national code\n\nRef country code: AT\n\nRef legal event code: MK07\n\nRef document number: 237351\n\nCountry of ref document: AT\n\nKind code of ref document: T\n\nEffective date: 20121120\n\n2013-01-31 PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]\n\nRef country code: GB\n\nFree format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION\n\nEffective date: 20121119\n\n2013-02-06 REG Reference to a national code\n\nRef country code: GR\n\nRef legal event code: MA\n\nRef document number: 20030402661\n\nCountry of ref document: GR\n\nEffective date: 20121121\n\n2013-08-01 REG Reference to a national code\n\nRef country code: ES\n\nRef legal event code: FD2A\n\nEffective date: 20130801\n\n2013-08-14 REG Reference to a national code\n\nRef country code: IE\n\nRef legal event code: MM4A\n\n2013-10-31 PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]\n\nRef country code: IE\n\nFree format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION\n\nEffective date: 20121120\n\nRef country code: ES\n\nFree format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION\n\nEffective date: 20121121"
    }
}